Literature DB >> 2087326

Intrathecal methadone: a dose-response study and comparison with intrathecal morphine 0.5 mg.

L Jacobson1, C Chabal, M C Brody, R J Ward, L Wasse.   

Abstract

The analgesic and adverse effects of intrathecal methadone 5 mg, 10 mg and 20 mg were assessed and compared with intrathecal morphine 0.5 mg. The study was conducted on 38 patients who underwent total knee or hip replacement surgery. The intrathecal opioid was administered at the end of surgery and assessments began 1 h thereafter and continued for 24 h. Pain measurements, supplementary analgesia requirements, and adverse effects were recorded. Intrathecal morphine 0.5 mg provided effective and prolonged analgesia. Intrathecal methadone 5 mg, 10 mg, and 20 mg produced good analgesia of 4 h duration. Thereafter the median pain scores with intrathecal methadone were consistently higher (worse) than those with intrathecal morphine (P less than 0.05). The time to the onset of discomfort severe enough to require supplemental morphine was longer after intrathecal morphine than following methadone (15 h with morphine 0.5 mg; 6.25 h, 6.5 h and 6 h with methadone 5 mg, 10 mg, and 20 mg respectively: P less than 0.05). Central nervous system depression manifesting as respiratory depression, hypotension, and excessive drowsiness occurred in 3 of 8 patients injected with methadone 20 mg intrathecally. Generalized pruritus, nausea, vomiting, and urinary retention were common and equally distributed among the treatment groups. We conclude that both intrathecal morphine 0.5 mg and methadone 5, 10, and 20 mg provide excellent analgesia but that morphine has a more prolonged effect. Methadone 20 mg produced unacceptable side effects. Clinical evidence for rostral spread of methadone within the CSF, as indicated by facial itching and excessive drowsiness, was less apparent with 5 mg than with 10 and 20 mg. Various explanations for the observed differences between the drugs are discussed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2087326     DOI: 10.1016/0304-3959(90)91066-r

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  4 in total

Review 1.  Methadone for treatment of cancer pain.

Authors:  John Bryson; Anoo Tamber; Dori Seccareccia; Camilla Zimmermann
Journal:  Curr Oncol Rep       Date:  2006-07       Impact factor: 5.075

2.  Methadone in the intrathecal treatment of chronic nonmalignant pain resistant to other neuroaxial agents: the first experience.

Authors:  Y Eugene Mironer; C David Tollison
Journal:  Neuromodulation       Date:  2001-01

3.  Efficacy of Intrathecal Morphine in a Model of Surgical Pain in Rats.

Authors:  Aurelie Thomas; Amy Miller; Johnny Roughan; Aneesa Malik; Katherine Haylor; Charlotte Sandersen; Paul Flecknell; Matthew Leach
Journal:  PLoS One       Date:  2016-10-26       Impact factor: 3.240

Review 4.  Non-dermatological Challenges of Chronic Itch.

Authors:  Andreas E Kremer; Thomas Mettang; Elke Weisshaar
Journal:  Acta Derm Venereol       Date:  2020-01-07       Impact factor: 3.875

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.